ESTRING

ApprovedSmall molecule

UUniversity of California, San Francisco

ESTRING is one of 38 small molecule programs targeting Recurrent urinary tract infections. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Urinary Tract InfectionsActive, not recruiting

Breast CancerActive, not recruiting

Recurrent Urinary Tract InfectionsApproved

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

ESTRING

UUniversity of California, San Francisco

Approved

1 2

Lexiscan

Astellas

Preclinical

1 3

Adenocard

Astellas

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Chantix

PPrism Pharmaceuticals

Preclinical

1 7

Chirocaine

PPurdue Pharma LP

Preclinical

1 8

Acupan

YYonsei University

Preclinical

1 9

Paracetamol

GSK

Preclinical

1 10

Zoladex

Luye Pharma Group Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalActive, not recruiting

Recurrent Urinary Tract Infections

NCT06353269

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients

Completed·UUniversity of California, San Francisco·Phase 2·NCT00698035·76 enrolled

Vaginal Dryness1 trial

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

Active, not recruiting·PPolly A. Niravath, MD·Phase 2·NCT01984138·33 enrolled

Recurrent urinary tract infections1 trial

Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections

Active, not recruiting·UUniversity of California, Irvine·Phase 4·NCT06353269·111 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ESTRING. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ESTRING compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ESTRING. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of California, San Francisco

ESTRING

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Breast Cancer1 trial

Vaginal Dryness1 trial

Recurrent urinary tract infections1 trial

References

Drug Info

Quick Facts

Related News